Drug Trial Radar · NCT05731271
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
111
Actual
Start
Feb 8, 2023
Primary completion
Jun 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question\[s\] it aims to answer are: * What is the recommended dose patients can safely receive? * How long does this drug remain in the body after administration? * What are the side effects of this drug? * Does your cancer respond to TST003? * Participants on this study will get TST003 intravenously (through a needle into your vein), once every 3 weeks. * You may need to come to the study site 2-4 times to have tests to see if you are eligible to be in the study before you begin to receive the study drug. * After you start the study drug, you will need to return to the site several times after each dose so the physician can take vital signs, draw blood samples, and evaluate you for safety and wellbeing. * Participants will continue taking the drug as long as they are receiving clinical benefit. * At the end of your study participation, additional testing is required.
Conditions
- Locally Advanced Solid Tumor
- Metastatic Tumor
- Colorectal Adenocarcinoma
Interventions
TST003Drug
IV humanized anti-GREM1 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the Dose limiting toxicities of TST003Time frame: Observed during the first 21 day cycle
- Assess Adverse events (AEs) of TST003Time frame: through study completion, an average of 1 year
- Assess abnormal findings related to TST003Time frame: through study completion, an average of 1 year
- assess the Overall Response Rate of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)Time frame: through study completion, an average of 1 year
- assess the Duration of Response of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)Time frame: through study completion, an average of 1 year
- assess the Time to Response of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)Time frame: through study completion, an average of 1 year
- assess the Disease Control Rate of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)Time frame: through study completion, an average of 1 year
- assess the Progression Free Survival of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)Time frame: through study completion, an average of 1 year
- assess the Overall Survival of TST003 as monotherapy at the RP2D in subjects with locally advanced or metastatic GREM1 positive solid tumors (Phase 1bPart)Time frame: through study completion, an average of 1 year
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
OHSU
Portland, Oregon
Mary Crowley
Dallas, Texas
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.